Furie, R., Tummala, R., Kalunian, K., Morand, E., Abreu, G., Vollenhoven, R. v., . . . Al-Mossawi, H. (2024). LBO1 DORIS remission in patients with SLE treated with anifrolumab or placebo during the 4-year TULIP-LTE trial: Post hoc analysis. BMJ Publishing Group.
Chicago Style (17th ed.) CitationFurie, Richard, Raj Tummala, Kenneth Kalunian, Eric Morand, Gabriel Abreu, Ronald van Vollenhoven, Catharina Lindholm, and Hussein Al-Mossawi. LBO1 DORIS Remission in Patients with SLE Treated with Anifrolumab or Placebo During the 4-year TULIP-LTE Trial: Post Hoc Analysis. BMJ Publishing Group, 2024.
MLA引文Furie, Richard, et al. LBO1 DORIS Remission in Patients with SLE Treated with Anifrolumab or Placebo During the 4-year TULIP-LTE Trial: Post Hoc Analysis. BMJ Publishing Group, 2024.